BRCA2 and prostate cancer: Similar to ENOC, in prostate cancer, RB1 loss is associated with poorer survival: early somatic co-deletion of BRCA2 and RB1 is associated with an aggressive, castration-resistant prostate cancer subtype characterized by epithelial-to-mesenchymal transition and shorter survival (30).